Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

A Highly Efficient Recombineering-Based Method for Generating Conditional Knockout MutationsPreprint

Liu, P., Jenkins, N. A., & Copeland, N. G. (2003) · Genome Research · doi:10.1101/gr.749203 · Cited by 1,013

‘Knobs-into-holes’ engineering of antibody C H 3 domains for heavy chain heterodimerization

Ridgway, J. B., Presta, L. G., & Carter, P. M. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.7.617 · Cited by 816

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794

Targeting the β secretase BACE1 for Alzheimer's disease therapy

Yan, R., & Vassar, R. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 645

Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622

Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation

Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549

Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants

Bien‐Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., Luk, W., Lu, Y., Dennis, M. S., Weimer, R. M., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131660 · Cited by 356

Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier

Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., Solanoy, H. O., Tong, R. K., Hoyte, K., Luk, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005338 · Cited by 278

A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo

Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274

Developing Therapeutic Antibodies for Neurodegenerative Disease

Yu, Y. J., & Watts, R. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0187-4 · Cited by 231

Antibody Approaches To Treat Brain Diseases

Neves, V., Aires‐da‐Silva, F., Côrte‐Real, S., & Castanho, M. A. R. B. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.10.005 · Cited by 63

Antibody transcytosis across brain endothelial-like cells occurs nonspecifically and independent of FcRn

Ruano-Salguero, J. S., & Lee, K. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-60438-z · Cited by 63

Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA.

Pizzo, M. E., Plowey, E. D., Khoury, N., Kwan, W., Abettan, J., DeVos, S. L., Discenza, C. B., Earr, T., Joy, D., Lye-Barthel, M., et al. (2025) · Science · doi:10.1126/science.ads3204 · Cited by 63

Novel Peptides Derived from Dengue Virus Capsid Protein Translocate Reversibly the Blood–Brain Barrier through a Receptor-Free Mechanism

Neves, V., Aires‐da‐Silva, F., Morais, M., Gano, L., Ribeiro, E., Pinto, A. R. T., Aguiar, S. I., Gaspar, D., Fernandes, C., Correia, J. D. G., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00087 · Cited by 61

Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-β

Sehlin, D., Fang, X. T., Meier, S. R., Jansson, M., & Syvänen, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-17358-2 · Cited by 58

Investigating receptor-mediated antibody transcytosis using blood–brain barrier organoid arrays

Simonneau, C., Duschmalé, M., Gavrilov, A., Brandenberg, N., Hoehnel, S., Ceroni, C., Lassalle, E., Kassianidou, E., Knoetgen, H., Niewoehner, J., et al. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00276-x · Cited by 65

Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies

Pardridge, W. M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1230195 · Cited by 55

Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil

Giugliani, R., Martins, A. M., So, S., Yamamoto, T., Yamaoka, M., Ikeda, T., Tanizawa, K., Sonoda, H., Schmidt, M., & Sato, Y. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.019 · Cited by 62

Brain Penetrating Bifunctional Erythropoietin–Transferrin Receptor Antibody Fusion Protein for Alzheimer’s Disease

Chang, R., Maghribi, A. A., Vanderpoel, V., Vasilevko, V., Cribbs, D. H., Boado, R. J., Pardridge, W. M., & Sumbria, R. K. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00594 · Cited by 53

Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?

Cavaco, M. C., Gaspar, D., Castanho, M. A. R. B., & Neves, V. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010062 · Cited by 55

Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy

van den Broek, S. L., Shalgunov, V., & Herth, M. M. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213125 · Cited by 57

A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils – a new concept for neuroimaging

Syvänen, S., Fang, X. T., Hultqvist, G., Meier, S. R., Lannfelt, L., & Sehlin, D. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.01.004 · Cited by 53

The Promises and Challenges of Erythropoietin for Treatment of Alzheimer’s Disease

Sun, J., Martin, J. M., Vanderpoel, V., & Sumbria, R. K. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08524-y · Cited by 56

Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain

Gadkar, K., Yadav, D. B., Zuchero, J. Y., Couch, J. A., Kanodia, J., Kenrick, M. K., Atwal, J. K., Dennis, M. S., Prabhu, S., Watts, R. J., et al. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.01.009 · Cited by 52

Harnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins

Chadarevian, J. P., Davtyan, H., Chadarevian, A. L., Nguyen, J., Capocchi, J. K., Le, L., Escobar, A., Chadarevian, T., Mansour, K., Deynega, E., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.009 · Cited by 60

Alzheimer’s therapy targeting the β-secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies

Ohno, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.007 · Cited by 51

Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration

Hanzatian, D. K., Schwartz, A. J., Gizatullin, F., Erickson, J., Deng, K., Villanueva, R., Stedman, C., Harris, C., Ghayur, T., & Goodearl, A. D. J. (2018) · mAbs · doi:10.1080/19420862.2018.1465159 · Cited by 54

Functional selection of protease inhibitory antibodies

Lopez, T., Mustafa, Z., Chen, C., Lee, K. B., Ramirez, A., Benitez, C., Luo, X., Ji, R., & Ge, X. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903330116 · Cited by 51

Widespread brain distribution and activity following i.c.v. infusion of anti‐β‐secretase (BACE1) in nonhuman primates

Yadav, D. B., Maloney, J. A., Wildsmith, K. R., Fuji, R. N., Meilandt, W. J., Solanoy, H., Lu, Y., Peng, K., Wilson, B., Chan, P., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14021 · Cited by 49

PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder

Brown, A., Patel, S., Ward, C., Lorenz, A. S., Ortiz, M., DuRoss, A. N., Wieghardt, F., Esch, A. M., Otten, E. G., Heiser, L. M., et al. (2016) · Scientific Reports · doi:10.1038/srep31750 · Cited by 47

VHHs as tools for therapeutic protein delivery to the central nervous system

Wouters, Y., Jaspers, T., Rué, L., Serneels, L., Strooper, B. D., & Dewilde, M. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00374-4 · Cited by 49

Opportunities and challenges in developing relevant animal models for Alzheimer’s disease

Felice, F. G. D., & Munoz, D. P. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.006 · Cited by 50

The insulin receptor is expressed and functional in cultured blood-brain barrier endothelial cells but does not mediate insulin entry from blood to brain

Hersom, M., Helms, H. C. C., Schmalz, C., Pedersen, T. Å., Buckley, S. T., & Brodin, B. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00350.2016 · Cited by 48

Blood-Spinal Cord Barrier: Its Role in Spinal Disorders and Emerging Therapeutic Strategies

Chopra, N., Menounos, S., Choi, J. P., Hansbro, P. M., Diwan, A. D., & Das, A. (2021) · NeuroSci · doi:10.3390/neurosci3010001 · Cited by 51

Two‐Step Targeted Hybrid Nanoconstructs Increase Brain Penetration and Efficacy of the Therapeutic Antibody Trastuzumab against Brain Metastasis of HER2‐Positive Breast Cancer

He, C., Li, J., Cai, P., Ahmed, T., Henderson, J. T., Foltz, W. D., Bendayan, R., Rauth, A. M., & Wu, X. Y. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201705668 · Cited by 47

Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain

Pardridge, W. M. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.602236 · Cited by 46

Kinetics of Blood–Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor

Pardridge, W. M. (2021) · Pharmaceuticals · doi:10.3390/ph15010003 · Cited by 46

Passive Aβ Immunotherapy: Current Achievements and Future Perspectives

Schilling, S., Rahfeld, J., Lues, I., & Lemere, C. A. (2018) · Molecules · doi:10.3390/molecules23051068 · Cited by 48

Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics

Zhong, X., & D’Antona, A. M. (2021) · Antibodies · doi:10.3390/antib10020013 · Cited by 45

Protein–Polymer Conjugates Synthesized Using Water-Soluble Azlactone-Functionalized Polymers Enable Receptor-Specific Cellular Uptake toward Targeted Drug Delivery

Kim, J. S., Sirois, A. R., Cegla, A. J. V., Jumai’an, E., Murata, N., Buck, M. E., & Moore, S. J. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00155 · Cited by 44

Transferrin receptor targeting by de novo sheet extension

Sahtoe, D. D., Coscia, A., Mustafaoğlu, N., Miller, L. M., Olal, D., Vulovic, I., Yu, T.-Y., Goreshnik, I., Lin, Y., Clark, L. E., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021569118 · Cited by 43

Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice

Zhao, P., Xu, Y., Fan, X., Li, L., Li, X., Arase, H., Tong, Q., Zhang, N., & An, Z. (2022) · mAbs · doi:10.1080/19420862.2022.2107971 · Cited by 46

Acute myeloid leukemia targets for bispecific antibodies

Hoseini, S. S., & Cheung, N. V. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.2 · Cited by 44

Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer’s Disease Cell Model

Liang, H., Shi, Y., Kou, Z., Peng, Y., Chen, W., Li, X., Li, S., Wang, Y., Wang, F., & Zhang, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140733 · Cited by 43

Transferrin receptor expression and role in transendothelial transport of transferrin in cultured brain endothelial monolayers

Hersom, M., Helms, H. C. C., Pretzer, N., Goldeman, C., Jensen, A. I., Severin, G. W., Nielsen, M. S., Holm, R., & Brodin, B. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.08.009 · Cited by 43

Altered blood–brain barrier transport in neuro-inflammatory disorders

Schenk, G. J., & de Vries, H. E. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.07.002 · Cited by 44

Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis

Chang, H.-Y., Wu, S., Li, Y., Zhang, W., Burrell, M. R., Webster, C. I., & Shah, D. K. (2021) · mAbs · doi:10.1080/19420862.2021.1874121 · Cited by 42

Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models

Israel, L. L., Galstyan, A., Cox, A., Shatalova, E. S., Sun, T., Rashid, M.-H., Grodzinski, Z., Chiechi, A., Fuchs, D.-T., Patil, R., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c10034 · Cited by 41

Receptor–mediated transcytosis of macromolecules across the blood–brain barrier

Baghirov, H. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2255138 · Cited by 44

Pharmacokinetics of Bispecific Antibody

Chen, Y., & Xu, Y. C. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0090-5 · Cited by 40

Therapeutic antibodies: A new era in the treatment of respiratory diseases?

Sécher, T., Guilleminault, L., Reckamp, K. L., Amanam, I. U., Plantier, L., & Heuzé‐Vourc'h, N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.003 · Cited by 42

Method of establishing breast cancer brain metastases affects brain uptake and efficacy of targeted, therapeutic nanoparticles

Wyatt, E. A., & Davis, M. E. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10108 · Cited by 40

Therapeutic antibodies – natural and pathological barriers and strategies to overcome them

Ojaimi, Y. A., Blin, T., Lamamy, J., Gracia, M., Pitiot, A., Denevault‐Sabourin, C., Joubert, N., Pouget, J., Gouilleux‐Gruart, V., Heuzé‐Vourc'h, N., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108022 · Cited by 43

A truncated and dimeric format of an Affibody library on bacteria enables FACS‐mediated isolation of amyloid‐beta aggregation inhibitors with subnanomolar affinity

Lindberg, H., Härd, T., Löfblom, J., & Ståhl, S. (2015) · Biotechnology Journal · doi:10.1002/biot.201500131 · Cited by 39

Targeting Transferrin Receptor 1 for Enhancing Drug Delivery Through the Blood–Brain Barrier for Alzheimer’s Disease

Shen, X., Li, H., Zhang, B., Li, Y., & Zhu, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199793 · Cited by 45

Erratum: Acute myeloid leukemia targets for bispecific antibodies

Hoseini, S. S., & Cheung, N. V. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.35 · Cited by 38

Direct, long-term intrathecal application of therapeutics to the rodent CNS

Ineichen, B. V., Schnell, L., Gullo, M., Kaiser, J., Schneider, M. P., Mosberger, A. C., Good, N., Linnebank, M., & Schwab, M. E. (2016) · Nature Protocols · doi:10.1038/nprot.2016.151 · Cited by 37

Drug delivery strategies to cross the blood-brain barrier in Alzheimer’s disease: a comprehensive review on three promising strategies

de Koning, L. A., Vazquez-Matias, D. A., Beaino, W., Vugts, D. J., van Dongen, G. A. M. S., van der Flier, W. M., Ries, M. G., van Vuurden, D. G., Vijverberg, E. G. B., & van de Giessen, E. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100204 · Cited by 41

Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins

Pardridge, W. M. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114234 · Cited by 40

VHH-Based Bispecific Antibodies Targeting Cytokine Production

Nosenko, M. A., Atretkhany, K. N., Mokhonov, V. V., Efimov, G. A., Kruglov, A., Tillib, S. V., Drutskaya, M. S., & Nedospasov, S. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01073 · Cited by 36

Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform

Pekar, L., Busch, M., Valldorf, B., Hinz, S. C., Toleikis, L., Krah, S., & Zielonka, S. (2020) · mAbs · doi:10.1080/19420862.2020.1812210 · Cited by 36

Risk of developing psoriasis in patients with schizophrenia: a nationwide retrospective cohort study

Yu, S., Yu, C.-L., Huang, Y., Tu, H., & Lan, C.-C. E. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14303 · Cited by 36

FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models

Weeden, T., Picariello, T., Quinn, B., Spring, S. M., Shen, P.-Y., Qiu, Q., Vieira, B. F., Schlaefke, L., Russo, R. J., Chang, Y.-A., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00733-w · Cited by 37

A new era in brain drug delivery: Integrating multivalency and computational optimisation for blood–brain barrier permeation

Porro, G., Basile, M., Xie, Z., Tuveri, G. M., Battaglia, G., & Lopes, C. D. F. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115637 · Cited by 39

From the Blood to the Central Nervous System

Fullstone, G., Nyberg, S., Tian, X., & Battaglia, G. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.06.001 · Cited by 37

Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor

Pardridge, W. M., & Chou, T. (2021) · Pharmaceuticals · doi:10.3390/ph14060535 · Cited by 35

Prospective Design of Anti‐Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain

Kanodia, J., Gadkar, K. G., Bumbaca, D., Zhang, Y., Tong, R., Luk, W., Hoyte, K., Lu, Y., Wildsmith, K., Couch, J., et al. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12081 · Cited by 34

Probing the brain with molecular fMRI

Ghosh, S., Harvey, P., Simon, J. C., & Jasanoff, A. (2018) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2018.03.009 · Cited by 33

Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier

Shin, J.-W., An, S., Kim, D., Kim, H., Ahn, J.-H., Eom, J., You, W., Yun, H., Lee, B., Sung, B., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100338 · Cited by 33

Bioassay Development for Bispecific Antibodies—Challenges and Opportunities

Register, A. C., Tarighat, S. S., & Lee, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105350 · Cited by 32

Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases

Zafir‐Lavie, I., Sherbo, S., Goltsman, H., Badinter, F., Yeini, E., Ofek, P., Miari, R., Tal, O., Liran, A., Shatil, T., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.017 · Cited by 31

Characterization of basigin monoclonal antibodies for receptor-mediated drug delivery to the brain

Christensen, S. C., Krogh, B. O., Jensen, A. D., Andersen, C. B. F., Christensen, S., & Nielsen, M. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-71286-2 · Cited by 31

Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice

Castellanos, D. M., Sun, J., Yang, J., Ou, W., Zambon, A. C., Pardridge, W. M., & Sumbria, R. K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090852 · Cited by 32

Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview

Lan, H., Chen, M., Yao, S.-Y., Chen, J., & Jin, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1266450 · Cited by 34

Advanced translational PBPK model for transferrin receptor-mediated drug delivery to the brain

Sato, S., Liu, S., Goto, A., Yoneyama, T., Okita, K., Yamamoto, S., Hirabayashi, H., Iwasaki, S., & Kusuhara, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.012 · Cited by 33

Novel Human/Non-Human Primate Cross-Reactive Anti-Transferrin Receptor Nanobodies for Brain Delivery of Biologics

Rué, L., Jaspers, T., Degors, I. M. S., Noppen, S., Schols, D., Strooper, B. D., & Dewilde, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061748 · Cited by 32

Basigin Antibodies with Capacity for Drug Delivery Across Brain Endothelial Cells

Christensen, S. C., Hudecz, D., Jensen, A. D., Christensen, S., & Nielsen, M. S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02421-x · Cited by 30

The role of iron transporters and regulators in Alzheimer’s disease and Parkinson’s disease: Pathophysiological insights and therapeutic prospects

Tian, S., Wang, B., Ding, Y., Zhang, Y. L., Yu, P., Chang, Y.-Z., & Gao, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117419 · Cited by 29

Bispecific brain-penetrant antibodies for treatment of Alzheimer’s disease

Sehlin, D., Hultqvist, G., Michno, W., Aguilar, X., Dahlén, A. D., Cerilli, E., Bucher, N. M., van den Broek, S. L., & Syvänen, S. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100214 · Cited by 29

Beyond the Walls of Troy: A Scoping Review on Pharmacological Strategies to Enhance Drug Delivery Across the Blood–Brain Barrier and Blood–Tumor Barrier

Pinkiewicz, M., Zaczyński, A., Walecki, J. M., & Zawadzki, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157050 · Cited by 36

Targeting Ligands Deliver Model Drug Cargo into the Central Nervous System along Autonomic Neurons

Sellers, D. L., Tan, J. Y., Pineda, J. M. B., Peeler, D. J., Porubsky, V. L., Olden, B. R., Salipante, S. J., & Pun, S. H. (2019) · ACS Nano · doi:10.1021/acsnano.9b01515 · Cited by 29

Therapeutic TVs for Crossing Barriers in the Brain

Zhao, Z., & Zloković, B. V. (2020) · Cell · doi:10.1016/j.cell.2020.06.041 · Cited by 30

Blood–brain borders: a proposal to address limitations of historical blood–brain barrier terminology

Badaut, J., Ghersi‐Egea, J., Thorne, R. G., & Konsman, J. P. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00478-5 · Cited by 31

Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes

Feng, Y., Wang, Y., Zhu, Z., Li, W., Sussman, R. T., Randall, M. P., Bosse, K. R., Maris, J. M., & Dimitrov, D. S. (2016) · mAbs · doi:10.1080/19420862.2016.1155014 · Cited by 29

Nanotherapeutics for Gene Modulation that Prevents Apoptosis in the Brain and Fatal Neuroinflammation

Kim, S. S., Rait, A. S., Garrido-Sanabria, E. R., Pirollo, K. F., Harford, J. B., & Chang, E. H. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.003 · Cited by 28

Antibody screening using a human iPSC‐based blood‐brain barrier model identifies antibodies that accumulate in the CNS

Georgieva, J. V., Goulatis, L. I., Stutz, C. C., Canfield, S. G., Song, H. W., Gastfriend, B. D., & Shusta, E. V. (2020) · The FASEB Journal · doi:10.1096/fj.202000851r · Cited by 30

Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening

Aguiar, S. I., Dias, J., André, A. S., Silva, M., Martins, D., Carrapiço, B., Castanho, M. A. R. B., Carriço, J. A., Cavaco, M. C., Gaspar, M. M., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101598 · Cited by 30

Next-generation antibody-based therapies in neurology

Ruck, T., Nimmerjahn, F., Wiendl, H., & Lünemann, J. D. (2021) · Brain · doi:10.1093/brain/awab465 · Cited by 29

Modular Chemical Construction of IgG-like Mono- and Bispecific Synthetic Antibodies (SynAbs)

Thoreau, F., Szijj, P. A., Greene, M. K., Rochet, L. N. C., Thanasi, I. A., Blayney, J. K., Maruani, A., Baker, J. R., Scott, C. J., & Chudasama, V. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01437 · Cited by 28

Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides

Lin, J., Yu, Z., & Gao, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c06851 · Cited by 28

Conjugation to a transferrin receptor 1-binding Bicycle peptide enhances ASO and siRNA potency in skeletal and cardiac muscles

Østergaard, M. E., Carrer, M., Anderson, B. A., Afetian, M. E., Bakooshli, M. A., Santos, J. A., Klein, S., Capitanio, J. S., Freestone, G. C., Tanowitz, M., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf270 · Cited by 34

Brain metastasis models: What should we aim to achieve better treatments?

Masmudi‐Martín, M., Zhu, L., Sánchez‐Navarro, M., Priego, N., Casanova-Acebes, M., Ruiz‐Rodado, V., Giralt, E., & Valiente, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.002 · Cited by 27

ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein

Bonvicini, G., Syvänen, S., Andersson, K. G., Haaparanta‐Solin, M., Lopez‐Picon, F. R., & Sehlin, D. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00324-y · Cited by 25

Investigating surrogate cerebrospinal fluid matrix compositions for use in quantitative LC-MS analysis of therapeutic antibodies in the cerebrospinal fluid

Fogh, J. R., Jacobsen, A., Nguyen, T. T. T. N., Rand, K. D., & Olsen, L. R. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02403-3 · Cited by 27

Delivery of Intravenously Administered Antibodies Targeting Alzheimer’s Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis

Tashima, T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020411 · Cited by 27

Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody

Faresjö, R., Sehlin, D., & Syvänen, S. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00435-2 · Cited by 23

Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads

Leandro, K., Rufino‐Ramos, D., Breyne, K., Ianni, E. D., Lopes, S., Nobre, R. J., Kleinstiver, B. P., Perdigão, P. R. L., Breakefield, X. O., & de Almeida, L. P. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115346 · Cited by 27

Dual targeting of transferrin receptor and CD98hc enhances brain exposure of large molecules

Wells, R. C., Akkapeddi, P., Chan, D., Joy, D. A., Moshkforoush, A., Chau, R., Chow, J., Cherf, G. M., Chien, E. Y. T., Clemens, A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116038 · Cited by 27

Bidirectional apical–basal traffic of the cation-independent mannose-6-phosphate receptor in brain endothelial cells

Siupka, P., Hersom, M., Lykke‐Hartmann, K., Johnsen, K. B., Thomsen, L. B., Andresen, T. L., Moos, T., Abbott, N. J., Brodin, B., & Nielsen, M. S. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17700665 · Cited by 23

Iron uptake at the blood-brain barrier is influenced by sex and genotype

Wade, Q. W., Chiou, B., & Connor, J. R. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.02.005 · Cited by 24

Type I interferon underlies severe disease associated with Junín virus infection in mice

Hickerson, B. T., Sefing, E. J., Bailey, K. W., Wettere, A. J. V., Penichet, M. L., & Gowen, B. B. (2020) · eLife · doi:10.7554/elife.55352 · Cited by 25

AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System

Marino, M., & Holt, M. G. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.870799 · Cited by 24

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Guo, X., Wu, Y., Ying, X., Xie, N., & Shen, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291836 · Cited by 26

Engineering small-molecule and protein drugs for targeting bone tumors

Wang, Y., Wang, C., Meng, X., Tian, Z., Zhou, J., Berger, J. M., Zhang, X. H.-F., & Xiao, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.001 · Cited by 24

Paradoxes of the EphB1 receptor in malignant brain tumors

Wei, W., Wang, H., & Ji, S. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0384-z · Cited by 24

A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6

Robert, R., Juglair, L., Lim, E. X., Ang, C., Wang, C. J. H., Ebert, G., Dolezal, O., & Mackay, C. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184278 · Cited by 24

Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease

Sumner, I. L., Edwards, R. A., Asuni, A. A., & Teeling, J. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00254 · Cited by 24

Single domain antibody-scFv conjugate targeting amyloid β and TfR penetrates the blood–brain barrier and interacts with amyloid β

Faresjö, R., Sjöström, E. O., Dallas, T. D., Berglund, M. M., Eriksson, J., Sehlin, D., & Syvänen, S. (2024) · mAbs · doi:10.1080/19420862.2024.2410968 · Cited by 25

Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice

Sun, J., Boado, R. J., Pardridge, W. M., & Sumbria, R. K. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00369 · Cited by 23

Seeing Is Believing: Nuclear Imaging of HIV Persistence

Henrich, T. J., Hsue, P. Y., & VanBrocklin, H. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02077 · Cited by 22

Transferrin' bispecific antibodies across the blood–brain barrier

Bray, N. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4522 · Cited by 16

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794

Novel Human/Non-Human Primate Cross-Reactive Anti-Transferrin Receptor Nanobodies for Brain Delivery of Biologics

Rué, L., Jaspers, T., Degors, I. M. S., Noppen, S., Schols, D., Strooper, B. D., & Dewilde, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061748 · Cited by 32

O1‐06‐02: Enhancing antibody uptake in brain to target BACE1

Atwal, J., Yu, J., Zhang, Y., Chen, Y., Chiu, C., Meilandt, W. J., Scearce-Levie, K. A., Lu, Y., Kenrick, M., Prabhu, S., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.234

Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants

Bien‐Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., Luk, W., Lu, Y., Dennis, M. S., Weimer, R. M., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131660 · Cited by 356